Replies to post #173621 on Biotech Values

[oc631]

I had this PRAN play on the burner that I believed had a high probability of success. Rather than wait for the FDA to lift the suspension, I pretty much went all in on PRAN.

You have been real lucky so far. I said I was done bad-mouthing this company so I'll pose my response as questions. How can a company look at blinded data, decide it needs "cleaning" (withholding it for 4 months and counting), go on a roadshow promoting the PBT2 story, while tapping their ATM at increasingly higher prices? Doesn't this go against the rules concerning disclosure of material information? Does the company justify these actions by claiming they are running a safety study (primary endpoint)? Does anyone care if this is an active drug in HD (or AD for that matter)?